At Sygnature Discovery, our bioscientists collaborate closely with your Chemistry, Computational Chemistry, and DMPK teams. Together, we aim to provide carefully tailored, informative, and efficient drug screening services. We utilise state-of-the-art equipment to ensure that our drug screening services deliver fully characterised hit, lead, and candidate series.
Our scientists can support your project through the provision of reliable, flexible and robust Iterative screening to accelerate your Design-make-test-analyse cycle. In addition, we can undertake tailored Mechanism of Action (MOA) studies to provide a deep understanding of your compounds engagement with the target to inform your compound progression and design strategies.
Our commitment to excellence ensures that you receive the highest quality support for your drug discovery efforts. With our collaborative approach, state-of-the-art equipment, and expertise in Iterative screening and MOA studies, we empower you to make informed decisions and advance your drug development projects with confidence.